Dopamine synthesis capacity in patients with treatment-resistant schizophrenia

American Journal of Psychiatry

Volumn 169, Issue 11, 2012, Pages 1203-1210

  Demjaha, Arsime ^a   Murray, Robin M ^a   McGuire, Philip K ^a   Kapur, Shitij ^a   Howes, Oliver D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; FLUPENTIXOL DECANOATE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; SCHIZOPHRENIA; TREATMENT RESPONSE;

EID: 84868591380     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.12010144     Document Type: Article

References (40)

1. Lindenmayer JP: Treatment refractory schizophrenia. Psychiatr Q 2000; 71:373-384
2. Howes OD, Kapur S: The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 2009; 35:549-562
3. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, McGuire PK: Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl 2007; 51:s13-s18 (Pubitemid 350273183)
4. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM: Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009; 66:13-20
5. Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR, Murray RM, McGuire P: Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry 2011; 168:1311-1317
6. Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, Valmaggia L, Allen P, Murray R, McGuire P: Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 2011; 16:885-886
7. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97:8104-8109 (Pubitemid 30460780)
8. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D' Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB: Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93:9235-9240
9. Kapur S, Zipursky R, Jones C, Remington G, Houle S: Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514-520 (Pubitemid 30191189)
10. Talbot PS, Laruelle M: The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 2002; 12:503-511 (Pubitemid 35408701)
11. Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192:481-483
12. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P: A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57:553-559 (Pubitemid 30349435)
13. Abi-Dargham A, Laruelle M: Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005; 20:15-27 (Pubitemid 40092387)
14. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD: Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989; 146:905-908 (Pubitemid 19180972)
15. Duncan E, Wolkin A, Angrist B, San filipo M, Wieland S, Cooper TB, Rotrosen J: Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics. Biol Psychiatry 1993; 34:523-528 (Pubitemid 23338508)
16. McGuffin P, Farmer A, Harvey I: A polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991; 48:764-770
17. Conley RR, Kelly DL: Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50:898-911 (Pubitemid 34020701)
18. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276 (Pubitemid 18039085)
19. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR: What does the PANSS mean? Schizophr Res 2005; 79:231-238 (Pubitemid 41457263)
20. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed Washington, DC, American Psychiatric Association, 1994
21. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR: Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162:441-449 (Pubitemid 40343909)
22. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M: Imaging human mesolimbic dopamine transmission with positron emission tomography, part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23:285-300 (Pubitemid 36307573)
23. Patlak CS, Blasberg RG, Fenstermacher JD: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3:1-7 (Pubitemid 13129630)
24. Carlsson A, Lindqvist M: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963; 20:140-144
25. Miyamoto S, Duncan GE, Marx CE, Lieberman JA: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10:79-104 (Pubitemid 40139590)
26. Der-Ghazarian T, Charntikov S, Varela FA, Crawford CA, McDougall SA: Effects of repeated and acute aripiprazole or haloperidol treatment on dopamine synthesis in the dorsal striatum of young rats: comparison to adult rats. J Neural Transm 2010; 117:573-583
27. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P: Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 2004; 61:134-142 (Pubitemid 38146547)
28. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S: " Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 2007; 27:2979-2986 (Pubitemid 46438984)
29. Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S: D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology 2009; 34:662-671
30. Kolakowska T, Williams AO, Ardern M, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM: Schizophrenia with good and poor outcome, I: early clinical features, response to neuroleptics, and signs of organic dysfunction. Br J Psychiatry 1985; 146:229-239
31. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, Hwang DR, Huang Y, Haber SN, Laruelle M: Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010; 67:231-239
32. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A: Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994; 91:11651-11654 (Pubitemid 24356402)
33. Shotbolt P, Stokes PR, Owens SF, Toulopoulou T, Picchioni MM, Bose SK, Murray RM, Howes OD: Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol Med 2011; 41:2331-2338
34. Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ: 6- (18)F-DOPA PET study in patients with schizophrenia: positron emission tomography. Psychiatry Res 2000; 100:1-11
35. Vernaleken I, Kumakura Y, Cumming P, Buchholz HG, Siessmeier T, Stoeter P, Müller MJ, Bartenstein P, Gründer G: Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage 2006; 30:1332-1339
36. Ito H, Takano H, Takahashi H, Arakawa R, Miyoshi M, Kodaka F, Okumura M, Otsuka T, Suhara T: Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission? J Neurosci 2009; 29:13730-13734
37. Gründer G, Vernaleken I, Müller MJ, Davids E, Heydari N, Buchholz HG, Bartenstein P, Munk OL, Stoeter P, Wong DF, Gjedde A, Cumming P: Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 2003; 28:787-794
38. Grace AA, Bunney BS, Moore H, Todd CL: Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 1997; 20:31-37 (Pubitemid 26421230)
39. Valenti O, Cifelli P, Gill KM, Grace AA: Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J Neurosci 2011; 31:12330-12338
40. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML: Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001; 41:237-260 (Pubitemid 32385889)